DEF 14A: ALX Oncology Holdings Inc. Sets Date for 2024 Annual Stockholder Meeting

ALX Oncology Holdings Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on director elections, executive compensation, and the ratification of the company's independent auditor.

Summary

• ALX Oncology Holdings Inc. will conduct its 2024 Annual Meeting of Stockholders via live webcast on June 12, 2024, at 1:00 p.m. Pacific Time.
• Stockholders of record as of April 15, 2024, are entitled to vote on the election of three Class I directors, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board of directors recommends voting FOR the election of Corey Goodman, Jason Lettmann, and Sophia Randolph as Class I directors, FOR the advisory vote on executive compensation, and FOR the ratification of KPMG LLP.
• The proxy statement and annual report are available online starting April 22, 2024.
• Stockholders can vote via the Internet, telephone, or mail, with deadlines for Internet and telephone voting set for 11:59 p.m. Eastern Time on June 11, 2024.
• The company's board consists of eight members, with six deemed independent under Nasdaq rules.
• Director compensation includes cash retainers and equity awards, with an annual limit of $1,000,000 for non-employee directors.
• The audit committee has appointed KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• In 2023, audit fees paid to KPMG LLP were $1,368,200, and tax fees were $13,354.
• The company has established an Executive Incentive Compensation Plan, allowing for cash incentive awards based on performance goals.
• The company has entered into change in control and severance agreements with its named executive officers, providing certain benefits upon termination or change in control.
• The company's largest stockholders include entities affiliated with venBio Partners (19.3%), FMR LLC (14.9%), and Redmile Group LLC (9.5%).
• The company has engaged in related-party transactions, including agreements with Tallac Therapeutics and the acquisition of ScalmiBio, Inc.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone. The company is adhering to corporate governance best practices and providing transparency to stockholders. However, the reported net loss tempers the overall sentiment.

Positives

• The company is adhering to good corporate governance practices by seeking stockholder ratification of the auditor appointment.
• The board of directors is actively involved in risk oversight at both the board and committee levels.
• The company is committed to ethical, responsible, and sustainable business practices, including diversity and inclusion.
• The company offers competitive pay and benefits, including equity ownership, to its employees.
• The company emphasizes employee development and training.
• The company has a Compensation Recovery Policy in place.

Negatives

• The company reported a net loss of $(160,805,000) in 2023.
• The company has engaged in related-party transactions, which may raise concerns about potential conflicts of interest.

Risks

• The classification of the board of directors may delay or prevent changes in control of the company.
• Related-party transactions could present potential conflicts of interest.
• The company's success depends on attracting, developing, and maintaining key talent in a competitive industry.
• The company's executive compensation program is subject to scrutiny and must be carefully designed to align with company performance and stockholder interests.

Future Outlook

The company intends to submit the executive compensation of its named executive officers to an advisory vote at its annual meeting of stockholders each year, consistent with the say-when-on-pay recommendation from its stockholders at its 2023 annual meeting, until such time as the say-when-on-pay proposal is brought before its stockholders again.

Management Comments

• On behalf of the Company's Board of Directors, we would like to thank you for your continued support of and interest in ALX.
• Our board of directors believes that a virtual Annual Meeting allows for participation by a broader group of stockholders, reduces the costs to stockholders associated with holding an in-person meeting, and is the best option for ensuring the health and safety of the participants.

Industry Context

The document reflects standard corporate governance practices for a publicly traded biotechnology company, including staggered board terms, independent committees, and executive compensation programs designed to align with company performance and stockholder value. The company's focus on immuno-oncology and collaboration agreements aligns with current trends in the biotechnology industry.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is consistent with industry practices for publicly traded biotechnology companies.
• The use of an independent compensation consultant (Compensia) to benchmark executive compensation against peer companies is a common practice.
• The company's related-party transaction policy is in line with regulatory requirements and aims to ensure transparency and fairness.
• The virtual annual meeting format has become increasingly common among public companies, particularly in the biotechnology sector, to enhance accessibility and reduce costs.
• The company's largest stockholders, including venBio Partners, FMR LLC, and Redmile Group LLC, are well-known institutional investors in the biotechnology industry.

Management Changes

Related Party Transactions

• In January 2017, Dr. Jaume Pons, our current President and Chief Scientific Officer, entered into a consulting agreement with venBio, one of our stockholders and an affiliate of one of our directors, Dr. Corey Goodman, to provide assistance with deal generation, evaluate potential investments and serve on boards of venBio's portfolio companies.
• In July 2020, we assigned to Tallac Therapeutics our lease with respect to our premises located at 866 Malcolm Road, Burlingame, California 94010, and received a sublease for such premises from Tallac Therapeutics.
• In July 2020, we also entered into a research and development services agreement, or the Tallac Services Agreement, with Tallac Therapeutics.
• In March 2021, we entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which we expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.
• On October 4, 2021, we entered into a share purchase agreement by and among us, ScalmiBio, Inc., or ScalmiBio, and the stockholders of ScalmiBio.

Stakeholder Impact

• Stockholders have the opportunity to vote on key corporate governance matters.
• Executive officers are incentivized to achieve company performance goals and increase stockholder value.
• Employees benefit from competitive pay, benefits, and equity ownership opportunities.
• The company's commitment to ethical and sustainable business practices can positively impact the broader community.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, KPMG, Audit Committee, Corporate Governance, ALX Oncology